Page 263 - Glucose Monitoring Devices

270 CHAPTER 13 Low glucose suspend systems

every 5 min based on sensor glucose and suspends or delivers insulin based on pre-
dicted sensor glucose values [60,61]. However, patient intervention is still required
to enter estimated carbohydrates in meals (to deliver boluses) and to possibly deliver
corrections. Future research is ongoing to close the loop without any patient inter-
ference. The details on the PLGS system, hybrid closed-loop system, and future
closed-loop systems can be found in the next chapters of this book.

References
[1] Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW,
Malanda B. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and
projections for 2045. Diabetes Research and Clinical Practice April 2018;138:271e81.
[2] Centers for Disease Control and Prevention. New CDC report: More than 100 million
Americans have diabetes or prediabetes. Available from: https://www.cdc.gov/media/
releases/2017/p0718-diabetes-report.html. [Accessed 18 December 2018].
[3] Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69e82.
[4] Shah VN, Moser E, Blau A, Dhingra M, Garg SK. Future of basal insulin. Diabetes
Technology and Therapeutics September 2013;15(9):727e32.
[5] Unnikrishnan R, Shah VN, Mohan V. Challenges in diagnosis and management of
diabetes in the young. Clinical Diabetes and Endocrinology November 10, 2016;2:
18. https://doi.org/10.1186/s40842-016-0036-6.
[6] Basu S, Yudkin JS, Kehlenbrink S, Davies JI, Wild SH, Lipska KJ, Sussman JB,
Beran D. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimula-
tion analysis. The Lancet Diabetes and Endocrinology November 20, 2018. https://
doi.org/10.1016/S2213-8587(18)30303-6 [Epub ahead of print].
[7] The Diabetes Control and Complications Trial Research Group. The effect of intensive
treatment of diabetes on the development and progression of long-term complications in
insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;329:
977e86.
[8] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of inten-
sive glucose control in type 2 diabetes. New England Journal of Medicine 2008;359:
1577e89.
[9] The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes
control and complications trial. The American Journal of Medicine 1991;90:450e9.
[10] Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR,
Rodriguez H, Rosenzweig J, Vigersky R. American diabetes association; endocrine
society: hypoglycemia and diabetes: a report of a workgroup of the American diabetes
association and the endocrine society. The Journal of Clinical Endocrinology and Meta-
bolism 2013;98:1845e59.
[11] Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D
exchange clinic registry. Diabetes Care 2015;38:971e8.
[12] Gubitosi-Klug RA, Braffett BH, White NH, et al. Tamborlane and the diabetes control
and complications trial (DCCT)/epidemiology of diabetes interventions and complica-
tions (EDIC) research group: risk of severe hypoglycemia in type 1 diabetes over 30
years of follow-up in the DCCT/EDIC study. Diabetes Care 2017;40:1010e6.